OREANDA-NEWS. Daphne Zohar, Co-founder and Chief Executive Officer of PureTech Health, a cross-disciplinary biotech company tackling fundamental healthcare needs in disruptive ways, yesterday was named the EY Entrepreneur Of The Year® 2016 in the New England programme. The awards programme, which is celebrating its 30th year, recognises entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities.

"It's an honour to be recognised among this distinguished group of business leaders and innovators," said Zohar. "The New England region has truly become a hub for fostering an entrepreneurial spirit and new ideas."

Sponsors

Founded and produced by EY, the Entrepreneur Of The Year Awards are nationally sponsored by SAP America, Merrill Corporation and the Ewing Marion Kauffman Foundation. In New England, sponsors also include fama PR, Goodwin Procter, the Isenberg School of Management at the University of Massachusetts Amherst, Nixon Peabody, True, Chatham Financial, Empire Valuation, Morgan Lewis and T3 Advisors.

About Daphne Zohar

Ms. Daphne Zohar is Co-Founder and Chief Executive Officer of PureTech Health (PRTC.L) and a member of the Company's Board of Directors. Zohar is an entrepreneur who built a new kind of biotech company in PureTech. Zohar assembled a leading team to help implement her vision, and she has attracted over $450 million to the Company and its businesses. Zohar has been recognised as a top leader and innovator in biotechnology by a number of sources, including BioWorld, MIT's Technology Review, the Boston Globe and Scientific American. She sits on the boards of PureTech Health, The Sync Project, Akili Interactive Labs, Follica, Karuna Pharmaceuticals and Tal Medical. She also sits on the Technology Development Fund Advisory Board at Children's Hospital Boston and is an Editorial Advisor to Xconomy, a national news company.

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary biotech company focused on areas of growing scientific and technical insights that it believes are at an important inflection point, including the central nervous, gastro-intestinal and immune systems, and the interactions and signalling between them. PureTech has approximately 20 clinical studies across its pipeline targeting multi-billion dollar market opportunities, including five human proof-of-concept studies and multiple pivotal or registration study readouts expected in the next two years. While inevitably some technologies will not advance to commercialisation, PureTech's approach mitigates risk as most of the cash resides on a PureTech parent company level, allowing PureTech to build value and divert cash to its most successful programmes as milestones are achieved. PureTech has over 220 patents and patent applications. PureTech's leading team and board, along with an advisory network of more than 60 expert founder-scientists and advisors across multiple disciplines, gives PureTech access to potentially ground-breaking science and technological innovation. With healthcare undergoing major transformation, PureTech believes it is well positioned to develop and launch medicines for the 21st century. For more information, visit www.puretechhealth.com and connect with us on Twitter.